Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504619 · ClinicalTrials.gov registry record · Phase 1
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
A Phase 1 study, sponsored by Gamida Cell.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02504619 is a Phase 1 study that was terminated before completion, run by Gamida Cell. The registered enrollment target is 1 participants.
The verdict
NCT02504619, a Phase 1 study, was terminated before completion, sponsored by Gamida Cell.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.
Interventions
- BIOLOGICAL CordIn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504619
The ClinicalTrials.gov registry entry for NCT02504619 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gamida Cell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CordIn is the first listed.
NCT02504619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02504619 about?
NCT02504619 is a clinical study titled "Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies". CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.
What is the current status of trial NCT02504619?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-04-04. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02504619?
The interventions under investigation include: CordIn (BIOLOGICAL).
Who is sponsoring clinical trial NCT02504619?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.